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ABSTRACT
Objectives: Our main objective was to assess
sociodemographic differences in the probability of
prenatal diagnosis of congenital heart defects (CHD);
we also looked at differences in termination of
pregnancy for fetal anomaly (TOPFA).
Design: Prospective cohort observational study.
Setting: Population-based cohort of CHD (live births,
TOPFA, fetal deaths) born to women residing in the
Greater Paris area (Paris and its surrounding suburbs,
N=317 538 total births).
Participants: 2867 cases of CHD, including 2348
(82%) live births, 466 (16%) TOPFA and 53 (2%) fetal
deaths.
Primary and secondary outcome measures:
Differences in the probability of prenatal diagnosis by
maternal occupation, geographic origin and place of
residence; differences in the probability of TOPFA.
Results: 29.1% (95% CI 27.5% to 30.8%) of all CHD
were prenatally diagnosed. Probability of prenatal
diagnosis was similar by maternal occupation,
geographic origin and place of residence. In contrast,
there were substantial differences in the probability of
TOPFA by maternal geographic origin; differences by
maternal occupation and place of residence were
generally smaller and not statistically significant.
Conclusions: Our findings suggest that an
appropriate health system organisation aimed at
providing universal, reimbursed specialised services to
all women can provide comparable access to prenatal
diagnosis for all sociodemographic groups. In contrast,
we found substantial differences in TOPFA for women
of different geographic origins, which may reflect
women’s preferences that should be respected, but that
can nonetheless lead to the situation where families
with fewer resources will be disproportionately
responsible for care of newborns with more severe
forms of CHD.
INTRODUCTION
Congenital heart defects (CHD) are the
most frequent group of major congenital
anomalies, accounting for almost 1% of all
births.1 2 Despite considerable progress in
the medical and surgical management of
CHD,3–7 they remain the most important
cause of infant mortality due to congenital
anomalies. Moreover, survivors may have con-
siderable short-term morbidity and long-term
adverse neurodevelopmental outcomes.8–16
Sociodemographic differences in use of
health services and outcomes are ubiquitous
and amply documented.17–20 This includes
the case of congenital anomalies21–25 even if
much of this literature is concerned with the
speciﬁc case of Down syndrome.23 26–29 Little
Strengths limitations of this study
▪ Our analyses were based on data from a large,
prospective, population-based cohort study of
congenital heart defects (CHD).
▪ There is paucity of information on sociodemo-
graphic differences in prenatal diagnosis of CHD,
which constitute an important group of congeni-
tal anomalies. This limitation in data is particu-
larly true in case of population-based data.
▪ We report an absence of disparities in prenatal
diagnosis of CHD; this constitutes an exception
rather than the rule in the studies of disparities
in health service use. This, in turn, suggests that
such disparities are not inevitable in the setting
of an appropriate healthcare organisation and
financing.
▪ We only examined a limited set of sociodemo-
graphic factors: maternal occupation, geographic
origin and department of residence. We lacked
data on maternal education, paternal education,
family income and other important individual-
level characteristics, as well as data on small
area-level indicators of socioeconomic context.
▪ We were not able to examine women’s knowl-
edge or preferences, including whether or not
the practices or outcomes of prenatal diagnosis
reflected their informed decision-making.
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population-based data exist on sociodemographic differ-
ences in the prevalence, diagnosis, management or out-
comes of CHD. In a retrospective population-based
cohort study, Pinto et al30 looked at census as well as
detailed clinical data in a state-wide surveillance pro-
gramme and found that the probability of prenatal diag-
nosis was not associated with census data. In another
study in the USA, using centre-based data for infants
who underwent surgery or catheter intervention, Peiris
et al31 found that individual-level sociodemographic
factors and medical insurance were associated with the
probability of prenatal diagnosis.
Prenatal diagnosis and optimal postnatal manage-
ment of CHD can result in secondary prevention of
mortality and improved long-term outcomes for
CHD.3–5 9 16 Sociodemographic disparities in prenatal
diagnosis of CHD could therefore lead to poorer out-
comes for groups with less access to prenatal diagnosis.
In addition, prenatal diagnosis can allow the opportun-
ity for women to make an informed decision regarding
their pregnancy, including the option of termination of
pregnancy for fetal anomaly (TOPFA) in case of severe,
incurable CHD.
France pursues an active policy of prenatal surveil-
lance with egalitarian intentions and well-codiﬁed rules
and regulations that aim at providing universal, reim-
bursed specialised services to all women. Three ultra-
sound examinations are recommended as part of the
programme for prenatal surveillance; one at the ﬁrst tri-
mester (11–14 weeks of gestation), a second one at the
second trimester (20–25 weeks) and a third around
34 weeks of gestation. In practice, a substantial number
of women have more than three ultrasound examina-
tions and only a small minority less than three.32
Prenatal diagnosis of structural congenital anomalies is
done for the most part at the second trimester ultra-
sound; only a small minority are detected either at the
ﬁrst or the third trimester (in particular, those associated
with intrauterine growth restriction) ultrasound examin-
ation. In case of severe, incurable anomalies, TOPFA is
authorised with no limit of gestational age after certiﬁca-
tion by two experts in dedicated centres for prenatal
diagnosis.
Using data from a population-based prospective
cohort study of CHD, we sought to assess any differences
in the probability of prenatal diagnosis of CHD by
maternal occupation, geographic origin and place of
residence; we did so for all CHD combined and, separ-
ately, for ‘isolated’ cases of CHD (ie, CHD excluding
those cases associated with chromosomal or other anom-
alies). We also looked at sociodemographic differences
in the probability of TOPFA.
MATERIALS AND METHODS
Data source
We used data from the EPICARD (EPIdémiologie des
CARDiopathies congénitales) study, which is a
population-based prospective cohort study with long-
term follow-up of all children with a CHD born to
women in the Greater Paris area (Paris and its surround-
ing suburbs). All cases (live births, TOPFA, fetal deaths)
diagnosed in the prenatal period or up to 1 year of age
in the birth cohorts between 1 May 2005 and 30 April
2008 born to women residing in Greater Paris were eli-
gible for inclusion. Diagnoses were conﬁrmed in specia-
lised paediatric cardiology departments and for the
majority of TOPFA and fetal deaths by a standardised
pathology examination. When a pathology examination
could not be done, the diagnoses were conﬁrmed by a
paediatric cardiologist (LH) and a specialist in echocar-
diography ( J-MJ) in the EPICARD study group, using
the results of prenatal echocardiography examination.
Multiple sources of data including all maternity units,
paediatric cardiology and cardiac surgery centres, fetal
and neonatal pathology departments, neonatal and
paediatric intensive units, infant units and outpatient
clinics in Greater Paris and a neighbouring tertiary care
centre were regularly consulted to attain completeness
of case registrations. Informed consent was obtained
from study participants. The last cases included in the
study were those in the 2008 birth cohort who were diag-
nosed in 2009. Follow-up of children in the EPICARD
cohort is ongoing and will include assessment of chil-
dren’s health and neurodevelopmental outcomes until
at least 8 years of age.
Details of coding and classiﬁcation of cases for the
EPICARD study are given elsewhere.33 Brieﬂy, two paedi-
atric cardiologists in the EPICARD study group (LH,
DB) attributed by consensus to each case, one, or in
<20% of cases, two or more six-digit code(s) of the long
list of the International Paediatric and Congenital
Cardiac Code (IPCCC).34 The IPCCC is a comprehen-
sive coding system (the long list of IPCCC includes
>10 000 individual codes) and its use in most clinical
and epidemiological studies requires regrouping of indi-
vidual anomalies. A newly proposed classiﬁcation, the
anatomic and clinical classiﬁcation of CHD (ACC-CHD),
accomplishes this regrouping on the basis of anatomic
and clinical criteria.33
Each case was classiﬁed into 1 (and only one) of the
10 main categories of the ACC-CHD. This classiﬁcation
scheme is based on a multidimensional approach
encompassing anatomy, echocardiography, clinical and
surgical management criteria. ACC-CHD includes 10
main categories, ordered in accordance with the direc-
tion of blood ﬂow, and 23 subcategories. It is designed
to use the code numbers of the long list of IPCCC but
can accommodate International Classiﬁcation of
Diseases, 10th Revision (ICD-10) codes.
Study population
Our initial study population included 2867 cases of
CHD (including live births, fetal deaths and TOPFA).
Information on prenatal diagnosis and TOPFA was avail-
able for all cases. In total, 274 (9.6%) cases had missing
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data for maternal occupation and 16 (0.6%) had
missing data for geographic origin of the mother; of the
latter, 13 (0.5%) cases had missing data on both mater-
nal profession and geographical origin. Overall, 277
(10%) cases had missing data on maternal profession
and/or geographical origin. The proportion of cases
with a prenatal diagnosis was comparable for cases with
complete information on maternal occupation and geo-
graphic origin (28.6%) versus for all cases (29.1%) com-
bined (ie, including those with missing data on maternal
occupation and/or geographic origin). The probability
of TOPFA after prenatal diagnosis was lower, 36.4%, for
cases with complete information on maternal occupa-
tion and geographic origin vs 41.4% for the overall study
population.
The maternal occupation data in our study come from
medical records. They reﬂect women’s ‘usual’ occupa-
tion at the time or right before pregnancy. On the basis
of occupation categories devised by the French National
Institute of Statistics and Economic Studies (INSEE), we
used the following maternal occupation categories,
which generally represent the order of highest to lowest
occupation categories in France: Professional (N=613),
Intermediate (N=492), Administrative/Public service
(N=309), Other (N=442) and None (N=737). The
Administrative/Public service category includes clerical
workers and lower echelon public service employees.
The group Other included the following categories that
comprised a relatively small number of women in each
category in our population: artisan, small business
owner, shopkeeper, shop assistant, service worker, skilled
worker and unskilled worker.
Data on geographic origin were based on women’s
declaration as noted in their medical records. In many
(most) cases, this reﬂects women’s place of birth.
However, this is not necessarily the case and geographic
origin in our data ultimately reﬂects how women deﬁne
their geographic origin. It is important to note that, in
France, it is in general illegal to obtain and record race
or ethnicity data. Hence, geographic origin should not
be equated with ethnicity. Moreover, women of the same
geographic origin may very well be of different ethnicity.
We classiﬁed the geographical origin of the mother
into four categories representing the major groups in
France: France (N=1370), North Africa (N=526), Other
(sub-Saharan) Africa (N=393) and Other origins
(N=562). The latter group mostly comprises women of
European origin other than France.
In total, 972 women in the study population were
residents of Paris, 702 residents of Hauts-de-Seine, 684
of Seine-Saint-Denis and 509 of Val-de-Marne; the latter
three are the adjoining suburbs of Paris. Even if import-
ant heterogeneities exist in the sociodemographic
characteristics of both residents of Paris and its
suburbs, particularly in case of Seine-Saint Denis, those
residing in the suburbs tend to have on average a lower
sociodemographic status as compared with residents of
Paris.
Statistical analysis
We calculated the proportion of cases with a prenatal
diagnosis and TOPFA after a prenatal diagnosis with
95% binomial exact CIs overall and by maternal occupa-
tion, geographic origin and place of residence for: (1)
all cases of CHD combined, (2) ‘isolated’ cases of CHD,
excluding those associated with chromosomal or other
anomalies; ‘isolated’ cases of CHD could include one or
more types of CHD but no other anomalies. We used
logistic regression models to estimate the adjusted
effects associated with maternal occupation, geographic
origin and place of residence on the odds of prenatal
diagnosis and TOPFA in models that also included
maternal age. We also estimated logistic models that
included all of the above plus categories of ACC-CHD in
order to take into account any variations that may exist
in the distribution of categories of CHD across socio-
economic groups; this was done as the probability of pre-
natal diagnosis and TOPFA is known to vary substantially
across different groups of CHD.1 6 35
RESULTS
Study population
Table 1 shows the characteristics of the study population.
The majority (60%) of women were 25–34 years of age
and approximately 30% were 35 years of age or older.
Almost half of all women were of French origin, 18%
from North Africa and 14% from other African origins.
Overall, 24% of women were in the Professional
(highest occupation) category and 28% declared no
maternal occupation. One-third of women resided in
Paris and the remaining were, in relatively similar pro-
portions, residents of the three surrounding suburbs of
Paris.
Prenatal diagnosis
Table 2 shows the proportion of all fetuses (live births,
stillbirths and TOPFA combined) which had a prenatal
diagnosis of CHD. Overall, 29% of all cases and 23% of
‘isolated’ cases of CHD were prenatally diagnosed. The
probability of prenatal diagnosis for all CHD was some-
what higher (adjusted OR 1.4, 95% CI 1.1 to 1.9) for
women aged 38 years and older; however, for ‘isolated’
CHD, there were no statistically signiﬁcant differences by
maternal age.
We also found essentially no signiﬁcant disparities in
the probability of prenatal diagnosis by maternal occupa-
tion, geographic origins or place of residence. This was
true both for all and ‘isolated’ cases of CHD. Moreover,
the adjusted ORs of prenatal diagnosis for all and iso-
lated cases of CHD estimated using a model that
included maternal occupation, geographic origin and
place of residence, as well as maternal age and categor-
ies of ACC-CHD, were close to one and the differences
were not statistically signiﬁcant (table 2). Additional
detailed descriptive data on the probability of prenatal
diagnosis by maternal characteristics as well as
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ACC-CHD groups are provided in online supplementary
annex 1.
Table 3 shows the proportion of prenatal diagnosis for
live births only. Overall, approximately 20% of all cases
and 18% of ‘isolated’ cases of CHD among live births
were prenatally diagnosed. Older women had higher
proportions of prenatal diagnosis for all CHD but not
for ‘isolated’ CHD only.
The proportions of prenatal diagnosis across the socio-
demographic groups examined were generally similar
and there was no evidence of lower odds of prenatal
diagnosis for women in lower occupation groups or
those from different geographic origins (table 3).
Terminations of pregnancy for fetal anomaly (TOPFA)
Table 4 shows the proportion of all and ‘isolated’ cases
of CHD with TOPFA following prenatal diagnosis of the
CHD. Overall, approximately 41% of all cases and 28%
of ‘isolated’ cases of CHD that were prenatally diagnosed
had a TOPFA. We found no statistically signiﬁcant differ-
ences in the probability of TOPFA by maternal age,
occupation or place of residence. However, the propor-
tion of cases with TOPFA was substantially lower for
women of African origin and those without a profession.
In the logistic regression models that adjusted the effects
for a given sociodemographic factor for its association
with others, there remained statistically signiﬁcant and
substantial differences in the adjusted odds of TOPFA by
geographic origin but not by maternal occupation or
place of residence. Women of African origin were less
than half as likely to opt for a TOPFA after prenatal
diagnosis of an ‘isolated’ CHD. Additional detailed
descriptive data on the probability of TOPFA by mater-
nal characteristics as well as ACC-CHD groups are pro-
vided in online supplementary annex 2.
DISCUSSION
In summary, using population-based data from 2867
cases of CHD, we found no evidence of socioeconomic
differences, by maternal occupation, geographic origin
or place of residence, in the probability of prenatal diag-
nosis of CHD. The likelihood of prenatal diagnosis was
similar across the sociodemographic groups both for the
total number of cases of CHD and for live births only.
We did, however, ﬁnd substantial differences in the prob-
ability of TOPFA after a prenatal diagnosis of CHD, par-
ticularly for women of different geographic origins. In
particular, women of African origin were more likely to
continue their pregnancy after prenatal diagnosis of
CHD. These ﬁndings were robust to adjustment for
maternal age and the spectrum of severity of CHD,
accounted for by an ACC-CHD.33
In general, absence of sociodemographic disparities in
health service utilisation and outcomes is the exception
rather than the rule.17–20 This is also the case in the
ﬁeld of congenital anomalies, although relatively
little data exist for anomalies other than Down syn-
drome.22–25 28 To the best of our knowledge, this is the
ﬁrst population-based study to speciﬁcally assess
individual-level sociodemographic differences in pre-
natal diagnosis and TOPFA of CHD. Our results imply
that the potential advantage of prenatal diagnosis, which
can lead to both a more informed decision regarding
the pregnancy and a more optimal postnatal manage-
ment of newborns with CHD, is equally shared across
sociodemographic groups in our population.
France pursues an active policy of prenatal surveil-
lance with egalitarian intentions. In spite of this policy,
previous studies have shown sociodemographic differ-
ences in prenatal screening, diagnosis and live birth
prevalence of Down syndrome in France.28 36 However,
it appears that disparities in prenatal diagnosis of Down
syndrome have decreased substantially over time,37 sug-
gesting that changes in practice and implementation of
policies aimed at universal reimbursed access to prenatal
diagnosis services have resulted in widespread diffusion
of prenatal screening services for Down syndrome for all
women. Our results further suggest that in the case of
Table 1 Characteristics of study population in the
EPICARD study
N Per cent
Age (year)
<25 313 11.0
25–34 1692 59.4
35–37 408 14.3
>37 435 15.3
Occupation
Professional 613 23.6
Intermediate 492 19.0
Administrative/Public service 309 11.9
Other 442 17.1
None 737 28.4
Geographic origin
France 1370 48.1
North African 526 18.4
Other African 393 13.8
Other origins 562 19.7
Department of residence
Paris 972 33.9
Hauts-de-Seine 702 24.5
Seine-Saint-Denis 684 23.9
Val-de-Marne 509 17.7
Congenital heart defects
Isolated 2031 70.8
Associated with chromosomal
anomalies
397 13.9
Associated with anomalies of other
systems
439 15.3
Pregnancy outcome
Live births 2348 81.9
TOPFA 466 16.3
Fetal deaths 53 1.8
EPICARD, EPIdémiologie des CARDiopathies congénitales;
TOPFA, termination of pregnancy for fetal anomaly.
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Table 2 Prenatal diagnosis of CHD according to maternal characteristics in the EPICARD study
Prenatal diagnosis
All CHD Isolated CHD*
N Per cent OR 95% CI
p
Value†
Adjusted
OR‡ 95% CI
p
Value† N Per cent OR 95% CI
p
Value†
Adjusted
OR‡ 95% CI
p
Value†
2867 29.1 27.5 to 30.8 2031 23.0 21.2 to 24.9
Age (year)
<25 313 29.7 1.1 0.8 to 1.4 0.09 1.0 0.7 to 1.4 0.09 222 23.9 1.0 0.7 to 1.5 0.86 0.9 0.6 to 1.4 0.53
25–34 1692 28.2 Ref Ref 1284 23.2 Ref Ref
35–37 408 27.9 1.0 0.8 to 1.3 1.0 0.8 to 1.4 280 21.4 0.9 0.7 to 1.2 1.1 0.7 to 1.6
>37 435 34.3 1.3 1.1 to 1.7 1.4 1.1 to 1.9 229 24.5 1.1 0.8 to 1.5 1.3 0.9 to 1.9
Occupation
Professional 613 26.9 Ref Ref 0.11 Ref Ref 0.39 467 20.8 Ref Ref 0.05 Ref Ref 0.34
Intermediate 492 28.3 1.1 0.8 to 1.4 1.2 0.9 to 1.7 385 23.1 1.1 0.8 to 1.6 1.1 0.8 to 1.7
Administrative/
Public service
309 23.6 0.8 0.6 to 1.2 0.8 0.6 to 1.2 236 16.5 0.8 0.5 to 1.1 0.7 0.4 to 1.1
Other 442 29.6 1.1 0.9 to 1.5 1.0 0.7 to 1.4 295 24.4 1.2 0.9 to 1.7 1.1 0.7 to 1.7
None 737 31.3 1.2 1.0 to 1.6 1.0 0.7 to 1.5 500 25.8 1.4 1.0 to 1.8 1.1 0.7 to 1.7
Geographic origin
France 1370 27.7 Ref Ref 0.12 Ref Ref 0.62 1030 21.8 Ref Ref 0.24 Ref Ref 0.90
North African 526 28.1 1.0 0.8 to 1.3 0.9 0.7 to 1.3 360 21.9 1.0 0.8 to 1.3 0.9 0.6 to 1.3
Other African 393 33.6 1.3 1.0 to 1.7 1.2 0.8 to 1.6 251 25.5 1.2 0.9 to 1.7 1.1 0.7 to 1.7
Other origins 562 30.6 1.1 0.9 to 1.4 1.1 0.8 to 1.4 380 26.3 1.3 1.0 to 1.7 1.0 0.7 to 1.4
Department of residence
Paris 972 28.8 Ref Ref 0.31 Ref Ref 0.13 702 21.1 Ref Ref 0.39 Ref Ref 0.44
Hauts-de-Seine 702 29.5 1.0 0.8 to 1.3 1.1 0.8 to 1.4 523 23.3 1.1 0.9 to 1.5 1.2 0.9 to 1.7
Seine-Saint-Denis 684 31.3 1.1 0.9 to 1.4 0.9 0.7 to 1.2 428 25.5 1.3 1.0 to 1.7 1.0 0.7 to 1.5
Val-de-Marne 509 26.3 0.9 0.7 to 1.1 0.8 0.6 to 1.0 378 23.5 1.2 0.9 to 1.6 0.9 0.6 to 1.3
*Isolated CHD: excluding chromosomal or other anomalies.
†p Value of the Wald test.
‡Adjusted OR for age, geographic origin, occupation, department of residence and categories of CHD (ACC-CHD33).
ACC, anatomic and clinical classification; CHD, congenital heart defects; EPICARD, EPIdémiologie des CARDiopathies congénitales.
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Table 3 Prenatal diagnosis of live births with CHD according to maternal characteristics in the EPICARD study
Prenatal diagnosis
All CHD Isolated CHD*
N
Per
cent OR 95% CI
p
Value†
Adjusted
OR‡ 95% CI
p
Value† N
Per
cent OR 95% CI
p
Value†
Adjusted
OR‡ 95% CI
p
Value†
2348 19.5 17.9 to 21.1 1885 17.5 15.8 to 19.2
Age (year)
<25 264 20.8 1.2 0.9 to 1.7 0.004 1.0 0.7 to 1.5 0.05 204 17.7 1.0 0.7 to 1.5 0.62 0.8 0.5 to 1.4 0.44
25–34 1409 18.0 Ref Ref 1183 17.1 Ref Ref
35–37 334 18.0 1.0 0.7 to 1.4 1.1 0.7 to 1.5 265 17.0 1.0 0.7 to 1.4 1.1 0.7 to 1.6
>37 322 26.7 1.7 1.3 to 2.2 1.6 1.1 to 2.2 217 20.7 1.3 0.9 to 1.8 1.3 0.9 to 2.0
Occupation
Professional 524 17.6 Ref Ref 0.07 Ref Ref 0.37 441 16.3 Ref Ref 0.09 Ref Ref 0.33
Intermediate 426 20.4 1.2 0.9 to 1.7 1.2 0.8 to 1.7 367 19.4 1.2 0.9 to 1.8 1.1 0.8 to 1.7
Administrative/
Public service
268 15.7 0.9 0.6 to 1.3 0.8 0.5 to 1.2 225 12.4 0.7 0.5 to 1.2 0.7 0.4 to 1.1
Other 366 21.0 1.3 0.9 to 1.8 1.1 0.7 to 1.6 273 19.1 1.2 0.8 to 1.8 1.1 0.7 to 1.7
None 621 22.9 1.4 1.0 to 1.9 1 0.7 to 1.5 465 20.4 1.3 0.9 to 1.8 1.0 0.7 to 1.7
Geographic origin
France 1129 17.5 Ref Ref 0.03 Ref Ref 0.68 958 16.3 Ref Ref 0.44 Ref Ref 0.96
North African 455 21.8 1.3 1.0 to 1.7 1.1 0.8 to 1.6 342 17.8 1.1 0.8 to 1.5 1.0 0.6 to 1.5
Other African 315 24.1 1.5 1.1 to 2.0 1.3 0.8 to 1.9 232 20.3 1.3 0.9 to 1.9 1.1 0.7 to 1.8
Other origins 437 19.2 1.1 0.8 to 1.5 1.0 0.7 to 1.4 343 19.0 1.2 0.9 to 1.7 1.0 0.7 to 1.5
Department of residence
Paris 794 18.6 Ref Ref 0.04 Ref Ref 0.10 657 16.1 Ref Ref 0.34 Ref Ref 0.50
Hauts-de-Seine 598 20.2 1.1 0.8 to 1.4 1.1 0.8 to 1.6 487 17.7 1.1 0.8 to 1.5 1.2 0.8 to 1.7
Seine-Saint-Denis 544 22.8 1.3 1.0 to 1.7 1.0 0.7 to 1.3 399 20.3 1.3 1.0 to 1.8 1.1 0.8 to 1.6
Val-de-Marne 412 15.5 0.8 0.6 to 1.1 0.7 0.5 to 1.0 342 16.4 1.0 0.7 to 1.5 0.9 0.6 to 1.3
*Isolated CHD: excluding chromosomal or other anomalies.
†p Value of the Wald test.
‡Adjusted OR for age, geographic origin, occupation, department of residence and categories of CHD (ACC-CHD33).
ACC, anatomic and clinical classification; CHD, congenital heart defects; EPICARD, EPIdémiologie des CARDiopathies congénitales.
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Table 4 Association between termination of pregnancy (TOPFA) and maternal characteristics in fetuses with prenatal diagnosis in the EPICARD study
TOPFA
All CHD Isolated CHD*
N
Per
cent OR 95% CI
p
Value†
Adjusted
OR‡ 95% CI
p
Value† N
Per
cent OR 95% CI
p
Value†
Adjusted
OR‡ 95% CI
p
Value†
835 41.4 38.1 to 44.9 468 27.6 23.6 to 31.9
Age (year)
<25 93 40.9 0.9 0.6 to 1.4 0.05 0.8 0.4 to 1.4 0.38 53 32.1 1.1 0.6 to 2.0 0.08 1.0 0.4 to 2.5 0.65
25–34 477 43.8 Ref Ref 298 30.2 Ref Ref
35–37 114 45.6 1.1 0.7 to 1.6 1.2 0.7 to 1.9 60 23.3 0.7 0.4 to 1.3 1.0 0.4 to 2.6
>37 149 31.5 0.6 0.4 to 0.9 0.7 0.5 to 1.2 56 14.3 0.4 0.2 to 0.8 0.5 0.2 to 1.5
Occupation
Professional 165 43.0 Ref Ref 0.08 Ref Ref 0.42 97 24.7 Ref Ref 0.61 Ref Ref 0.25
Intermediate 139 33.8 0.7 0.4 to 1.1 0.8 0.5 to 1.4 89 19.1 0.7 0.4 to 1.4 1.2 0.5 to 3.0
Administrative/
Public service
73 41.1 0.9 0.5 to 1.6 1.1 0.6 to 2.1 39 28.2 1.2 0.5 to 2.8 2.2 0.7 to 6.9
Other 131 38.9 0.8 0.5 to 1.3 1.2 0.7 to 2.1 72 27.8 1.2 0.6 to 2.3 2.5 0.9 to 6.6
None 231 30.3 0.6 0.4 to 0.9 0.8 0.4 to 1.3 129 20.9 0.8 0.4 to 1.5 1.1 0.4 to 2.9
Geographic origin
France 380 46.1 Ref Ref <0.0001 Ref Ref 0.0004 225 29.8 Ref Ref 0.08 Ref Ref 0.01
North African 148 26.4 0.4 0.3 to 0.6 0.4 0.2 to 0.6 79 16.5 0.5 0.2 to 0.9 0.2 0.1 to 0.5
Other African 132 34.9 0.6 0.4 to 0.9 0.6 0.3 to 1.0 64 25.0 0.8 0.4 to 1.5 0.4 0.1 to 1.0
Other origins 172 48.8 1.1 0.8 to 1.6 1.1 0.7 to 1.8 100 33.0 1.2 0.7 to 1.9 0.7 0.3 to 1.5
Department of residence
Paris 280 42.1 Ref Ref 0.25 Ref Ref 0.88 148 25.7 Ref Ref 0.14 Ref Ref 0.23
Hauts-de-Seine 207 38.7 0.9 0.6 to 1.2 0.9 0.6 to 1.4 122 27.1 1.1 0.6 to 1.8 1.2 0.6 to 2.5
Seine-Saint-Denis 214 38.8 0.9 0.6 to 1.3 0.9 0.6 to 1.5 109 22.9 0.9 0.5 to 1.5 0.5 0.2 to 1.2
Val-de-Marne 134 48.5 1.3 0.9 to 2.0 1.1 0.7 to 1.8 89 37.1 1.7 1.0 to 3.0 1.2 0.6 to 2.7
*Isolated CHD: excluding chromosomal or other anomalies.
†p Value of the Wald test.
‡Adjusted OR for age, geographic origin, occupation, department of residence and categories of CHD (ACC-CHD33).
ACC, anatomic and clinical classification; CHD, congenital heart defects; EPICARD, EPIdémiologie des CARDiopathies congénitales; TOPFA, termination of pregnancy for fetal anomaly.
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CHD there may be little if any important sociodemo-
graphic barriers to effective access to prenatal diagnostic
services. It is possible, however, that these results may
not necessarily be representative of other settings in
France, as the wide availability of specialised services in
our population is not always the case elsewhere.
In France, three ultrasound examinations are recom-
mended as part of the programme for prenatal surveil-
lance; one at the ﬁrst trimester (11–14 weeks of
gestation), a second at the second trimester (20–
25 weeks) and a third around 34 weeks of gestation. In
practice, a substantial number of women have more
than three ultrasound examinations and only a small
minority less than three.32 Prenatal diagnosis of struc-
tural congenital anomalies is done for the most part at
the second trimester ultrasound; only a small minority
are detected either at the ﬁrst (in particular neural tube
defects) or the third trimester (in particular those asso-
ciated with intrauterine growth restriction) ultrasound
examination. In 2005, the National Technical
Committee for Ultrasound Examinations issued recom-
mendations for a minimum of two images of the heart,
including the four-chamber and the short-axis views.
This guideline for fetal ultrasound examination has
come to be legally recognised and is likely to have con-
tributed to a generally higher quality of ultrasound
examination of the heart in our population.
In addition, the organisation of prenatal diagnostic
services is well codiﬁed and includes in particular the
constitution of 48 multidisciplinary centres for prenatal
diagnosis across the country, including four in Paris and
ﬁve in its surrounding suburbs. By law, the severity of
the fetal anomaly must be certiﬁed by two experts from
these centres in order for the TOPFA to be authorised.
For cases in which either TOPFA is not an appropriate
decision (‘curable’ or not sufﬁciently severe anomalies)
or for which women opt to continue their pregnancy
even if the experts consider that TOPFA is an acceptable
option, the centres play an important role in the peri-
natal management of cases to optimise care for mothers
and their affected newborns. Mandates for the exclusive
coordination of prenatal diagnosis services by these
multidisciplinary centres are likely to have contributed
to a wider availability of high-quality prenatal diagnostic
services in our population.
With regard to the sociodemographic differences
observed in the probability of TOPFA, to the extent that
these may reﬂect true differences in women’s prefer-
ences, they do not constitute a ‘problem’ to be remed-
ied. The primary objective of prenatal diagnosis,
including the option of TOPFA in case of severe, incur-
able anomalies, should be the opportunity for women to
make an informed choice38 regarding their pregnancy.
Hence, if women with certain sociodemographic
characteristics are more likely than others to opt for con-
tinuing their pregnancy after prenatal diagnosis of a
severe CHD, such differences in women’s decisions
should be respected. However, the possibility that such
apparent differences in preferences may in fact be in
part related to factors associated with healthcare provi-
ders, particularly miscommunication between providers
and pregnant women from different cultural back-
grounds, should also be considered.39
Approximately 10% of cases had missing information
for maternal occupation and/or geographic origin.
However, the proportion of cases with prenatal diagnosis
for those with complete information and the overall
study (including those with missing data) was essentially
the same, whereas the probability of TOPFA was some-
what (5%) lower for the cases with complete informa-
tion on sociodemographic characteristics versus the
overall study population. We have no à priori or empir-
ical reason to believe that this relatively small difference
may have biased our estimates of sociodemographic dif-
ferences in the probability of TOPFA. Although we
cannot be certain, it is likely that cases with TOPFA may
overall have less information available on sociodemo-
graphic characteristics of women and this is not neces-
sarily, or at least not predominantly, the case for some
sociodemographic groups more than others.
Another limit of our study is that we only assessed
sociodemographic differences across maternal occupa-
tion, geographic origin and place of residence using
broad categories. Certainly, sociodemographic status and
its possible effects on prenatal testing cannot be repre-
sented comprehensively using the characteristics
included in our study.40 In addition, we did not evaluate
women’s knowledge or preferences regarding prenatal
diagnosis and TOPFA for CHD. Hence, we cannot know
to what extent our results may reﬂect women’s effective
access to information and the possibility for informed
decision-making. Finally, despite the large number of
cases included in the cohort, we may have had relatively
limited power to assess the independent effects asso-
ciated with different dimensions of sociodemographic
status. Therefore, the absence of statistically signiﬁcant
differences in TOPFA for certain groups of maternal
occupation or by place of residence may have been in
part due to limited power in the adjusted models.
Our study leaves several questions unanswered. An
important set of questions relates to the possible existence,
and thereby potential implications of any sociodemo-
graphic differences that might exist in the prevalence and
the distribution of various types of CHD, which may in
turn affect the overall severity of CHD across sociodemo-
graphic groups. CHD represent a heterogeneous group of
anomalies33 41 42 that may affect various aspects of the
normal cardiac anatomy or function. Hence, a major chal-
lenge in evaluating clinical management and outcomes of
CHD relates to the great heterogeneity that exists in CHD
in terms of their prevalence, modalities of diagnosis, clin-
ical severity and treatment options among others.
In the case of our study, the notion of ‘severity’ of
CHD and how it should be deﬁned, particularly when
one is interested in sociodemographic differences in the
prenatal diagnosis of (or pregnancy termination for)
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CHD, does not seem obvious. The two well-established
scores of severity (Risk Adjustment for Congenital Heart
Surgery-1 method (RACHS-1) and Aristotle) are con-
cerned with surgical cases only. In addition, these scores
or any other classiﬁcations of CHD have not been for-
mally evaluated in terms of their ability to predict the
probability of prenatal diagnosis (or pregnancy
termination).
In a previous study, we found that prenatal diagnosis,
pregnancy termination and infant mortality differed
greatly across the categories of this classiﬁcation
(ACC-CHD6). Therefore, in the present study, we
adjusted our estimates of the associations between socio-
demographic factors and probabilities of prenatal diag-
nosis and pregnancy terminations for ACC-CHD.
However, the ACC-CHD classiﬁcation needs to be further
evaluated in terms of its predictive ability of probability of
prenatal diagnosis and terminations of CHD. Moreover, it
is not known whether or to what extent the prevalence of
different types of CHD (whether in categories or for indi-
vidual defects) may vary in relation to sociodemographic
factors, or how any such variabilities may be correlated
with clinical severity or probability (ease/modalities) of
prenatal diagnosis (eg, possibility of prenatal diagnosis by
a four-chamber view or not). We have undertaken a study
to examine some of these questions, which are beyond
the scope of the present one.
In conclusion, our results imply that the potential
advantage of prenatal diagnosis, which can lead to both a
more informed decision regarding pregnancy and a
more optimal postnatal management of newborns with
CHD, is equally shared across the sociodemographic
groups in our population. This is at least in part the result
of the active policy aimed at providing reimbursed univer-
sal access to prenatal diagnostic services for residents of
France. In addition, the wide availability of specialised
services in our population, as well as the well-codiﬁed
organisation of prenatal diagnostic services by multidis-
ciplinary centres for prenatal diagnosis, is likely to facili-
tate access to high-quality services in our population. The
sociodemographic differences we found in the probabil-
ity of TOPFA, particularly across categories of geographic
origin, may represent true differences in women’s prefer-
ences, but the role of healthcare providers, particularly
communication issues between providers and pregnant
women from different cultural backgrounds, should also
be taken into account. In any case, these differences in
TOPFA can result in disparities in the spectrum of sever-
ity of CHD at birth and thereby in the risk of adverse out-
comes. Hence, families with fewer resources may become
disproportionately responsible for the care of newborns
with more severe forms of CHD.
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